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ORIGINAL ARTICLE
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ABSTRACT
Background: Autoimmune polyendocrine syndrome type-1 (APS-1) is a rare, childhood onset
disease caused by mutations in the Autoimmune Regulator gene. The phenotypic expression
is highly variable and includes disease manifestations in the oral cavity, including mucocuta-
neous candidiasis. Increasing evidence suggests a potential role of the skin, oral and gut
microbiotas in the pathogenesis of autoimmunity. To date, no information exists regarding
the oral microbiota in APS-1.
Objective: To assess the bacterial microbiota of whole saliva in APS-1 patients by using high
throughput sequencing.
Design: Whole unstimulated saliva was collected from 10 APS-1 patients and 17 healthy
controls and examined by high throughput sequencing of the hypervariable region V1-V2 of
16S rRNA using the 454 GS Junior system. Metastats (http://cbcb.umd.edu/software/meta
stats) was used to analyse the pyrosequencing reads.
Results: A reduction in the total number of bacterial genera and species was detected in APS-
1 compared to healthy controls. The proportion of the major phyla Firmicutes was higher
(60% vs 41%, p = 0.002) and Bacteroidetes lower (15% vs 28%, p = 0.007) in APS-1 compared
to healthy controls. On the genus level, Streptococcus and Gemella were prevalent in APS-1.
Conclusion: Our findings indicate a significantly altered oral microbiota in APS-1.
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Autoimmune polyendocrine syndrome type-1
(APS-1) or autoimmune polyendocrinopathy-candi-
diasis-ectodermal dystrophy (OMIM 240300) is a
rare, monogenic, childhood onset disorder which
is clinically defined by the presence of two of the
three major disease components: primary adrenal
insufficiency, hypoparathyroidism, and chronic
mucocutaneous candidiasis (CMC) [1]. However,
the clinical picture is highly variable and includes
many minor disease components [2]. The
Autoimmune Regulator (AIRE) gene is the disease-
causing gene [3,4]. AIRE acts as a transcriptional
regulator and is almost exclusively expressed in the
thymus [5] where it orchestrates the process of
negative selection of self-reactive T cells and con-
tributes to the development of regulatory T cells
(Tregs) [6,7]. All patients present autoantibodies
against autoantigens expressed in the affected tissue
[8] and/or against immune mediators such as inter-
feron-omega (ω) and interleukin (IL)-22 [9,10].
Interestingly, circulating autoantibodies and AIRE-
mutations can be found before development of
clinical APS-1 [11,12] making the role of
environmental triggers particularly relevant in the
pathogenesis and phenotypic expression.
Increasing evidence indicates that the environment
shapes the human immune system and accounts for its
heterogeneity among individuals [13]. The oral, gut,
and skin microbiotas could play a key role in the patho-
genesis of systemic and organ-specific autoimmune
diseases [14]. Most APS-1 patients develop disease
components affecting the oral cavity; enamel hypoplasia
and CMC are both commonmanifestations [9,15]. Also
a Sjögren’s-like syndrome without extractable nuclear
antigen autoantibodies has recently been described
[15,16]. These oral manifestations probably interfere
with the homeostasis of the oral microbiota.
Furthermore, autoimmunity against defensins and
other antimicrobial substances as observed in APS-1
could change the microbiota [17]. Reduced salivary
flow rate changes the oral microbiota [18] and in a
study of patients with severe Sjögren’s syndrome
Streptococcus salivarius, Neisseria pharyngis,
Veillonella species, and Micrococcus mucilaginosus
were reduced and the number of Staphylococcus aureus
and Candida species were increased compared to
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healthy controls [19]. Another recent study of primary
Sjögren’s syndrome patients with normal salivary flow
rate found that the number of bacterial genera and
species was lower in patients, and concluded that saliva
dysbiosis is a key characteristic of primary Sjögren’s
syndrome [20]. Moreover, changes in the oral micro-
biota are found to be associated with several other
diseases including squamous cell carcinoma, athero-
sclerosis, bacteraemia, and rheumatoid arthritis [21].
In APS-1, no information exists regarding the oral
microbiota and only a few studies of the gut micro-
biota have been reported [17,22,23]. In this study, we
characterized the bacterial profile in whole unstimu-
lated saliva of patients by high throughput sequen-
cing, a technique which recovers both cultivated and
not-yet-cultivated bacteria, thus giving an in-depth
overview of bacteria present.
Materials and methods
Patients and clinical data
A total of 10 APS-1 patients from 6 different families
were included. All patients fulfilled the diagnostic cri-
teria of APS-1. They were previously described in the
Norwegian cohort [9,24,25] and included in our
National Registry of Autoimmune Diseases. Three
patients were excluded after an initial quality control.
A detailed characterization of the seven remaining
patients (five females and two males) is given in
Table 1. The mean age was 32.3 years (range 10–64).
All participants had their disease onset before the age of
8 years. Three patients presented the three major dis-
ease components and the mean number of disease
components was five (range 4–7). Enamel hypoplasia
was found in all patients. CMC was previously diag-
nosed in five patients and three had oral candidiasis at
the time of sampling (Table 1). Disease-causing AIRE-
mutations and autoantibodies against interferon-ω
were present in all. All participants gave informed and
written consent and the study was approved by The
Regional Committee for Medical and Health Research
Ethics for Western Norway.
Saliva sampling and sample processing
Whole unstimulated saliva was collected from patients
(n = 10) and healthy controls (n = 17) with the same age
and sex distributions as patients. Saliva samples were
collected between 9 a.m. and 11 a.m., and participants
were asked not to brush their teeth, eat, or drink for at
least 2 h before sampling. No participants were regular
smokers or had received antibiotics within the lastmonth
before sampling. Saliva pH was measured using a strip
Table 1. Characteristics of the APS-1 patients. The age at diagnosis for each disease component is written in parentheses. The
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21OH, 21-hydroxylase; 17OH, 17-α-hydroxylase; AADC, aromatic L-amino acid decarboxylase; Al, alopecia; AT, autoimmune thyroiditis; B12, vitamin-B12
deficiency; CMC, candidiasis; E, enamel hypoplasia; G, hypogonadism; GAD65, glutamic acid decarboxylase 65-kDA isoform; HP, hypoparathyroidism;
IL17, interleukin-17; IL22, interleukin-22; INF-ω, interferon-omega; M, malabsorption; MAGEB2, melanoma antigen B2; NALP5, NACHT leucine-rich-
repeat protein 5; PAI, primary adrenocortical insufficiency; PCA, parietal cell autoantibodies; PDILT, protein disulphide isomerase-like testis expressed;
SCC, side-chain-cleavage enzyme; SOX10, sex determining region Y-box 10; TGM4, transglutaminase 4; TPH1, tryptophan hydroxylase 1; TH, tyrosine
hydroxylase; V, vitiligo; YoB, year of birth, nd; not done.
*Standard methods were used for culturing Candida albicans.
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test (mColorpHast™ pH Test Strips, MilliporeSigma) and
standard methods were used for culturing Candida
albicans. Unstimulated saliva flow rate (ml/min) was
measured based on a collection period of 15 min
(Table 1). Samples were immediately stored at −80°C
until analysis.
Sample processing was done as previously described
[20,26]. In summary, DNA was extracted from a
250 µl sample volume using the MasterPure™ DNA
Purification kit (Epicentre, Illumina Company,
Madison, WI) and was dissolved in 45 µl 1 × TE
buffer. The 16S rRNA hypervariable region V1-V2
was amplified in three parallel PCRs and sequenced
on a 454 GS Junior System (Roche, Branford, CT).
Primer sequences and amplifications reactions are
given previously [20]. DNA quality and concentrations
were assessed with Bioanalyzer 2100 (Agilent, Santa
Clara, CA) and Nanodrop 3300 Flurospectrometer
(Thermo Scientific, Wilmington, DE), all within the
range to perform high throughput sequencing.
Bioinformatics analysis of sequence reads
Bioinformatics analysis of sequence reads was executed
as described previously [20]. In brief, raw sequence
reads were subjected to a species-level, reference-based
taxonomy assignment especially designed for studying
the human oral microbial community [20]. The set of
16S rRNA reference sequences previously published by
Al-Hebshi et al. [27] and the NCBI 16S rRNA reference
sequence set (ftp://ftp.ncbi.nlm.nih.gov/blast/db/
16SMicrobial.tar.gz) were combined giving reference
sequences representing a total of 1,151 oral and 12,013
non-oral species that were BLASTN-searched for each
of the sequence reads. Unassigned reads were then
screened for high-quality non-chimeras and subjected
to de novo species-level operational taxonomy unit call-
ing for potential novel species. The quantitative insights
into microbial ecology pipeline software package ver-
sion 1.9.1 [28] was used for down-stream analyses,
including alpha and beta diversities. A statistical
method introduced in Metastats (http://cbcb.umd.edu/
software/metastats) was used to reveal significant dif-
ferences between the microbiota of control saliva and
APS-1 saliva. This method employs a false discovery
rate to improve specificity in high complexity environ-
ments, and handles sparsely sampled features using
Fisher’s exact test [29]. p-values ≤ 0.05 were considered




An overview of the sequence read counts in each
analysis step is given in Supplemental Table 1.
Composition of the salivary microbiota of APS-1
patients
Five different phyla were detected in APS-1 patients
with DNA sequences predominately assigned to the
phyla Firmicutes (60%), Bacteroidetes (15%),
Proteobacteria (10%), Fusobacteria (8%), and
Actinobacteria (6%). Table 2 gives an overview of
the significantly different abundances of taxa from
control saliva and APS-1 saliva by phyla, genera and
species, respectively. In Figure 1, a comparison of the
bacterial content of saliva in APS-1 and controls
based on the sequencing of the hypervariable 16S
rDNA region V1-V2 is presented. Saliva from APS-
1 displayed a significantly increased relative abun-
dance of Firmicutes (p = 0.002) and a lower fre-
quency of Bacteroidetes (p = 0.007) compared with
controls (Figure 2).
A total of 64 bacterial genera were detected in
APS-1 and 90 in healthy controls. Figure 3 gives
the relative abundances of the 18 major genera
found in APS-1 samples and controls. Moreover,
a total of 18 genera showed significant differences
in abundances (Table 2). Metastats analyses
showed that the genera Streptococcus and
Gemella were significantly higher in patients than
controls (p = 0.0001 and 0.036, respectively;
Figure 4) whereas Prevotella and Veillonella were
significantly higher in controls (p = 0.001 and
<0.001, respectively; Figure 4). Among the genera
with significant difference in abundance, eight
genera were absent from whole saliva of APS-1
patients (Table 2).
In APS-1 patients, the sequencing data revealed
the most abundant species to be Streptococcus sp.
str. C300, Streptococcus multispecies spp.24_2,
Streptococcus mitis, Streptococcus infantis, and
Haemophilus parainfluenzae. Among these, only
Streptococcus sp. str. C300 and Streptococcus multi-
species spp.24_2 were increased compared to controls
(p = 0.001, 0.032, respectively). The other species
found more abundant in APS-1 patients were
Fusobacterium nucleatum subsp. animalis, Gemella
haemolysans, Ruminococcaceae [G-3] sp. Oral taxon
366, and Capnocytophaga ochracea (p = 0.046, 0.047,
<0.001, 0.002, respectively). The Veillonella parvula
group and Prevotella melaninogenica were most
abundant in controls. Table 2 shows all species with
significant differences in abundance compared to
control saliva and APS-1 saliva as estimated by
Metastats.
Species richness and diversity
Samples from healthy controls had a higher species
richness and diversity than APS-1 samples. Figure 5
(a) illustrates that the average species richness is
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higher in healthy subjects based on the observed
species rarefaction curves Figure 5(b,c) gives the
estimated species richness evaluated on the Chao1
matrix and the rarefaction curves based on the
Shannon index, respectively showing an overall dif-
ference in alpha diversity, although the latter shows
no difference between health and APS-1. However,
the Shannon index measures both richness and
abundance, hence the evenness of the community.
Figure 5(c) therefore indicates that there is no sig-
nificant difference between APS-1 and controls in
terms of species evenness. Finally, Figure 5(d) gives
Table 2. Differences in abundances of taxa in APS-1 and control saliva. Significant (p ≤ 0.05) differences in relative abundance of
taxa from control saliva and APS-1 saliva as estimated by Metastats http://cbcb.umd.edu/software/metastats. Differences
significant after Bonferonni Correction for multiple testing are marked with *.
Taxon APS-1 saliva (n = 7) Control saliva (n = 17) Metastat p-value
Phyla
Firmicutes 0.65118 ± 0.02551 0.41118 ± 0.02572 0.002
Bacteroidetes 0.11271 ± 0.03162 0.26009 ± 0.03845 0.007
Genera
Streptococcus 0.53448 ± 0.08523 0.18016 ± 0.01963 0.0001*
Gemella 0.01467 ± 0.00023 0.00253 ± 0.00062 0.036
Prevotella 0.05995 ± 0.01021 0.17357 ± 0.02970 0.001
Veillonella 0.04049 ± 0.00925 0.16254 ± 0.02760 0.0001*
Neissera 0.02065 ± 0.00965 0.05508 ± 0.01269 0.029
Actinomyces 0.00148 ± 0.00055 0.00673 ± 0.00159 0.002
Megashaera 0.00000 0.00631 ± 0.00287 0.027
Lachnospiraceae_ [G-3] 0.00059 ± 0.00033 0.00417 ± 0.00097 0.001
Lachnoanaerobaculum 0.00024 ± 0.00019 0.00123 ± 0.00033 0.008
Eubacterium_[XIVa][G-1] 0.00025 ± 0.00018 0.00109 ± 0.00031 0.019
Ruminococcaceae_[G-3] 0.00002 ± 0.00776 0.00119 ± 0.00448 0.016
Bacteroides 0.00000 0.00049 ± 0.00019 0.012
Veillonella 0.00000 0.00053 ± 0.00025 0.031
Bacteroidetes_[G-3] 0.00000 0.00032 ± 0.00010 0.002
Peptostreptococcaceae_[XI][G-4] 0.00000 0.00023 ± 0.00011 0.034
Mitsuokella 0.00000 0.00033 ± 0.00016 0.038
Desulfovibrio 0.00000 0.00405 ± 0.00040 0.018
Catonella 0.00000 0.00015 ± 0.00013 0.048
Species
Streptococcus sp._str._C300 0.12958 ± 0.03003 0.03065 ± 0.00618 0.001
Streptococcus multispecies_spp24_2 0.11555 ± 0.05022 0.00877 ± 0.00349 0.031
Fusobacterium nucleatum_ss_animalis 0.02401 ± 0.01178 0.00083 ± 0.00038 0.046
Gemella haemolysans 0.01308 ± 0.00599 0.00132 ± 0.00047 0.047
Capnocytophaga ochracea 0.00112 ± 0.00035 0.00004 ± 0.00002 0.023
Veillonella parvula_group 0.03273 ± 0.00653 0.10745 ± 0.01904 0.0003*
Prevotella melaninogenica 0.02205 ± 0.00876 0.09752 ± 0.01762 0.0002*
Veillonella atypica 0.00776 ± 0.00389 0.05509 ± 0.01369 0.001
Neisseria flavescens/subflava 0.01723 ± 0.00873 0.04995 ± 0.01204 0.023
Porphyromonas gingivalis 0.00000 0.02849 ± 0.01465 0.048
Prevotella pallens 0.00059 ± 0.00036 0.02308 ± 0.00617 0.0004*
Campylobacter concisus 0.00133 ± 0.00083 0.01390 ± 0.00382 0.001
Prevotella salivae 0.00054 ± 0.00024 0.00848 ± 0.00293 0.006
Prevotella veroralis_nov_95.28% 0.00000 0.00723 ± 0.00287 0.010
Solobacterium moorei 0.00251 ± 0.00121 0.00638 ± 0.00154 0.045
Megasphare micronuciformis 0.00000 0.00631 ± 0.00287 0.023
Atopobium parvulum 0.00099 ± 0.00026 0.00579 ± 0.00223 0.028
Lachnospiraceae_[G-3] sp._oral_taxon_100_nov_83.29% 0.00049 ± 0.00032 0.00342 ± 0.00082 0.001
Actinomyces sp._Oral_Taxon_180 0.00043 ± 0.00022 0.00328 ± 0.00103 0.006
Actinomyces odontolyticus 0.00047 ± 0.00015 0.00247 ± 0.00062 0.001
Prevotella multispecies_sppn1_2_nov_82.34% 0.00027 ± 0.00019 0.00158 ± 0.00579 0.026
Lachnoanaerobaculum orale 0.00024 ± 0.00019 0.00123 ± 0.00332 0.008
Eubacterium_[XIVa][G-1] saburreum 0.00025 ± 0.00018 0.00109 ± 0.00313 0.016
Tannerella forsythia_nov_96.52% 0.00000 0.00095 ± 0.00311 0.002
Aggregatibacter aphrophilus 0.00000 0.00080 ± 0.00035 0.018
Porphyromonas gingivalis_nov_96.46% 0.00000 0.00079 ± 0.00037 0.026
Leptotrichia sp._oral_taxon_219_nov_83.33% 0.00021 ± 0.00019 0.00077 ± 0.00020 0.039
Fretibacterium fastidiosum 0.00000 0.00074 ± 0.00033 0.019
Ruminococcaceae_[G-3] sp._oral_taxon_366_nov_78.83% 0.00002 ± 0.00002 0.00054 ± 0.00015 0.001
Veillonella sp._oral_taxon_780_nov_82.14% 0.00000 0.00053 ± 0.00025 0.029
Mogibacterium neglectum 0.00010 ± 0.00008 0.00051 ± 0.00190 0.044
Haemophilus parainfluenzae_nov_96.89% 0.00000 0.00043 ± 0.00026 0.018
Desulfovibrio sp._oral_taxon_040 0.00000 0.00040 ± 0.00040 0.018
Mitsuokella sp._Oral_Taxon_H31_nov_78.38% 0.00000 0.00033 ± 0.00016 0.035
Streptococcus constellatus_nov_80.22% 0.00000 0.00032 ± 0.00013 0.008
Porphyromonas gingivalis_nov_91.05% 0.00004 ± 0.00004 0.00032 ± 0.00011 0.019
Bacteroidetes_[G-3] sp._oral_taxon_280_nov_92.66% 0.00000 0.00031 ± 0.00010 0.015
Alloprevotella rava_nov_86.47% 0.00000 0.00029 ± 0.00009 0.002
Fretibacterium sp._oral_taxon_359 0.00000 0.00025 ± 0.00016 0.029
Prevotella sp._oral_taxon_515_nov_80.56% 0.00000 0.00024 ± 0.00013 0.018
Prevotella sp._oral_taxon_515_nov_78.25% 0.00000 0.00023 ± 0.00016 0.029
Peptostreptococcaceae_[XI][G-4] sp._oral_taxon_369 0.00000 0.00022 ± 0.00011 0.031
Catonella sp._oral_taxon_164_nov_95.73% 0.00000 0.00015 ± 0.00014 0.048
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a PCoA 3D plot of all samples with the distances
calculated using weighed normalized UniFrac
matrix, and clearly indicates that the two groups
have distinct beta diversity. Taken together, these
results show a richer diversity in controls compared
to APS-1.
Figure 1. Bacterial phyla detected in APS-1 patients (n = 7) and control saliva (n = 17). Comparison of microbiota in APS-1 and
healthy saliva determined by sequencing the hypervariable 16S rDNA region V1-V2. Relative abundance of the different phyla in
control and APS-1 samples is shown.
Figure 2. The relative abundances of the phyla Bacteroidetes and Firmicutes in saliva of healthy controls (n = 17) and APS-1
patients (n = 7) illustrated with boxplots. The lines indicate means and standard deviations.
Figure 3. Bacterial genera detected in saliva from APS-1 patients (n = 7) and controls (n = 17). Groups designated as ‘Other’
represents minor groups classified. The Y-axis represents relative abundance. An increase in the genus Streptococcus in APS-1
saliva relative to control saliva is demonstrated.
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Discussion
Increasing evidence suggests a potential role of the
skin, oral, and gut microbiotas in the pathogenesis of
autoimmunity [14]. Using high throughput sequen-
cing and a comprehensive bioinformatics approach to
analyse next generation 16S rDNA pyrosequencing
reads, we here present hitherto undescribed signifi-
cant differences in the composition of the salivary
microbiota comparing APS-1 patients and healthy
controls, indicating a possible contribution in patho-
genesis and clinical expression.
Figure 4. The relative abundances of the genera Streptococcus, Gemella, Prevotella, and Veillonella in saliva of healthy controls
(n = 17) and APS-1 patients (n = 7) illustrated with boxplots. The lines indicate means and standard deviations.
Figure 5. Comparison of microbial diversity in saliva samples of APS-1 patients (n = 7) and health samples (n = 17). Average
rarefaction curves of APS-1 and health samples reported as (a) observed species, (b) Chao1 estimator, (c) Shannon index, (d)
PCoA 3D plots of all samples with distances calculated using weighed normalized UniFrac matrix. Blue curves and dots represent
health samples; and red represents APS-1.
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The most striking differences were a higher por-
tion of Firmicutes and a reduction of Bacteroidetes
in APS-1 patients. Similar findings were recently
described in primary Sjögrens syndrome [20] and a
reduced species diversity and an altered ratio between
Firmicutes and Bacteroidetes were described in the
intestinal microbiota in several autoimmune diseases
[30–33]. However, Firmicutes represents a phylum
where most bacteria have a Gram-positive cell wall
including the oral genera Streptococcus, Lactobacillus,
Selenomonas, Clostridium, and Eubacterium. The
phylum Bacteroidetes is composed of Gram-negative
bacteria. On a genus level, Streptococcus and Gemella
were increased in APS-1. However, a reduction in the
total number of bacterial genera was seen. Overall,
these novel findings indicate a significant altered oral
microbiota in APS-1.
This is the first report on the oral microbiota in
APS-1, and only a few studies have investigated the
gut microbiota in patients [17,22,23]. A comparative
analysis of the intestinal microbiota of APS-1 patients
with gastrointestinal manifestations showed signifi-
cant enrichment of segmented filamentous bacteria
[17], which are Gram-positive commensal bacteria
with the potential to adhere to epithelial cells and
induce T helper (Th) 17 responses. Another study
reported that APS-1 patients develop early and sus-
tained responses to gut microbial antigens reminis-
cent to Crohn’s disease [23] linked to defects in
Tregs. Finally, products from commensal bacteria
have the potential to indirectly regulate thymic Aire
expression in mice [22]. Based on the above, this
indicates that the microbiota contributes in shaping
immunity in APS-1 although the molecular mechan-
isms are incompletely characterized.
Factors known to directly affect the immune sys-
tem, and consequently, the risk of autoimmunity,
such as genetics, gender, and diet may also exert
their effects by modulating microbiota profiles and
functions. Using animal models of experimental coli-
tis [34] and arthritis [35] it was shown that Gram-
negative bacteria, possibly through the TLR2/IL-10
axis, reduced inflammation [34], whereas Gram-posi-
tive bacteria contributed to a more severe disease
[35]. In a mouse model of Sjögren’s disease, depletion
of the intestinal microbiome worsened the ocular
response to desiccation, while the overall severity of
disease correlated with intestinal microbiome diver-
sity [36]. Two recent characterizations of the oral
microbiota in primary Sjögren’s syndrome demon-
strated a significant shift in the oral microbiota of
patients and reduced numbers of genera [20,37], sug-
gesting a role of the oral microbiota in the pathogen-
esis. Interestingly, these findings are comparable to
what we currently describe in APS-1.
CMC caused by C. albicans is the most common
and earliest manifestation of APS-1 [2]. The clinical
course varies from periodical to chronic and usually
affects the oral mucosa [1,2,9]. To date, neutralizing
autoantibodies against the Th17 cytokines IL-17A, IL-
17F, and IL-22 are suggested to explain the impairment
in mucosal immunity in APS-1 patients [10,38].
However, an important line of defence against oral
CMC is the oral microbiota that prevents infections
by their interplay with immune cells, nutrients, meta-
bolic products and by secreting antagonistic molecules,
which together balance local inflammatory responses
[39]. C. albicans can form biofilms with many oral
bacteria, including streptococci [40], which have syner-
gistic or antagonistic influences on C. albicans.
Noteworthy, recent work has highlighted the critical
role of metabolic products from specific gut microbiota
such as lactobacilli in priming IL-22 dependent muco-
sal immune responses by innate lymphoid cells via the
aryl hydrocarbon receptor, which is fundamental for
protection against uncontrolled local Candida expan-
sion [41]. Further, a shift in salivary microbiota has
been linked to the risk of oral cancer in selected groups
of patients [42]. We found significantly increased
abundance of streptococci in APS-1 saliva compared
to healthy controls and several streptococci were
among the most abundant species in APS-1 saliva. To
speculate, an altered microbiota may change the profile
of immune regulatory metabolic products, and thus,
contribute in altering immunity in APS-1 patients. Still
it remains unclear whether an altered microbiota
causes disease manifestations or the altered microbiota
is an effect of disease components.
The obvious drawbacks of this study are the low
number of patients included and the heterogeneity
within this group. Initially 10 patients were included
but technical issues with the sequencing made us
exclude 3 patients. We plan to include more patients
trying to correlate the different taxa to clinical man-
ifestations of APS-1 and calculate absolute microbial
abundances using a quantitative polymerase chain
reactions assay. The same approach could be used to
characterize the skin and the gut microbiotas in
APS-1.
In conclusion, the oral microbiota in APS-1
patients is altered compared to healthy controls
and seems to be a characteristic of the syndrome.
In general, the skin, oral, and intestinal microbio-
tas in APS-1 patients should be further investi-
gated to reveal their potentially contribution in
pathogenesis and phenotypic expression of the
syndrome.
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